Aimmune Lays Foundations In Europe For Lead Peanut Allergy Therapeutic
With Aimmune’s AR101 oral immunotherapeutic nearing the market in the EU and US, the company sketches out its European business strategy after ARTEMIS meets its primary endpoint.
With Aimmune’s AR101 oral immunotherapeutic nearing the market in the EU and US, the company sketches out its European business strategy after ARTEMIS meets its primary endpoint.